List view / Grid view
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
23 April 2015 | By Victoria White
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown)...
21 April 2015 | By Victoria White
MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015...
Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
11 March 2015 | By MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma...
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
5 February 2015 | By MRC Technology
MRC Technology has appointed Dr Edward Bliss in the new role of General Counsel and Company Secretary...
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
2 December 2014 | By MRC Technology
MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of a new Alzheimer’s drug...
24 November 2014 | By MRC Technology / Yabao Pharmaceuticals
MRC Technology and Yabao Pharmaceutical Co, Inc. today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease...
3 July 2014 | By MRC Technology
Initiative brings together global expertise to share compound libraries and streamline drug discovery...
Justin Bryans talks to Drug Target Review about his work as Director of Drug Discovery at the Centre for Therapeutics Discovery, MRC Technology. Justin is also a member of the Drug Target Review Editorial Board.
